Product Data Sheet

Cas No.:	875787-07-8	Cat. No:	PC14915
Product Name:	LXR-623		
Product synonym:	2-[(2-氯-4-氟苯基)甲基]-3-(4-氟苯基)-7-(三氟甲基)-2H-吲唑;LXR623 抑制剂		
Chemical name:	LXR-623		
MF:	C21N2F5CLH12	FW:	422.7784
Purity:	≥98%	Batch No.:	-
Storage:			
Structural formula:			
λmax:	-	Formulation:	-
Solubility :			
SMILES :	ClC1C([H])=C(C([H])=C([H])C=1C([H])([H])N1C(C2C([H])=C([H])C(=C([H])C=2[H])F)=C2C([H])=C([H])C([H])=C(C(F)(F)F)C2=N1)F		
InChI Code:	-		
InChI Key:			
WARNING This product is not for human or veterinary use.			

Product Description

肝X受体激动剂，LXR-623是可以渗透血脑屏障的 LXRα 部分激动剂和 LXRβ 完全激动剂，IC50 分别为24 nM 和 179 nM。

生物活性	LXR-623 is a brain-penetrant partial **LXRα** and full **LXRβ** agonist, with **IC_{50}**s of 24 nM and 179 nM, respectively.
IC50 & Target[1][2]	IC50: 24 nM (LXR-α), 179 nM (LXR-β)
体外研究(In Vitro)	LXR-623 potently kills U87EGFRvIII and GBM39 cells 体外研究 while completely sparing NHAs. LXR-623 also increases ABCA1 protein and decreases LDLR protein levels in all three cell lines. LXR-623 suppresses LDLR expression, increases expression of the ABCA1 efflux transporter, and induces substantial cell death in all of the GBM samples tested. LXR-623 (5 μM) also induces GBM cell death through activation of LXRβ. LXR-623 treatment of human PBMC 体外研究 significantly increases transcription of ABCA1 and ABCG1. **Medlife has not independently confirmed the accuracy of these methods. They are for reference only.**

体内研究(In Vivo)	LXR-623 (400 mg/kg, p.o.) crosses the blood-brain barrier, induces target gene expression, and achieves therapeutic levels in GBM cells in the brain with minimal activity in the periphery. LXR-623 inhibits tumor growth, promotes tumor cell death, and prolongs the survival of mice bearing intracranial patient-derived GBMs. LXR-623 (1.5, 5 mg/kg/day) significantly reduces progression of atherosclerosis in animals compared with the placebo group. WAY-252623 (15 and 50 mg/kg) results in a significant reduction of atherosclerosis in a dose-dependent manner. WAY-252623 (20, 60, and 120 mg/kg/day, p.o.) displays neutral lipid effects in this CETP-expressing Syrian hamster. Moreover, LXR-623 (50 mg/kg) induces gene expression in rodent peripheral blood cells in rat. LXR-623 (0, 15 and 50 mg/kg) dose-dependently upregulates transcription of ABCA1 and ABCG1 in monkey whole blood cells proportional to dose. **Medlife has not independently confirmed the accuracy of these methods. They are for reference only.**
包装储存	Powder **-20°C** 3 years **4°C** 2 years In solvent **-80°C** 6 months **-20°C** 1 month

溶解度数据

体外研究:

DMSO : ≥ 47 mg/mL (111.17 mM)

* "≥" means soluble, but saturation unknown.

配制储备溶液	溶剂体积 质量 浓度	1 mg	5 mg	10 mg
	1 mM	2.3653 mL	11.8265 mL	23.6530 mL
	5 mM	0.4731 mL	2.3653 mL	4.7306 mL
	10 mM	0.2365 mL	1.1826 mL	2.3653 mL

* 产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，**建议分装保存，避免反复冻融造成的产品失效**。

储备液的保存方式和期限： -80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 **体外研究** 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，**澄清的储备液可以根据储存条件，适当保存**；体内实验的工作液，**建议您现用现配，当天使用**； 以下溶剂前显示的百分比是指**该溶剂在您配制终溶液中的体积占比**；如在配制过程中出现沉淀、析出现象，可以通过**加热和/或超声的方式助溶**

1. 建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

   Solubility: ≥ 2.5 mg/mL (5.91 mM); Clear solution

   此方案可获得 ≥ 2.5 mg/mL (5.91 mM，饱和度未知) 的澄清溶液。

   以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

   将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液

2. 建议依照次序添加每种溶剂： 10% DMSO 90% corn oil

   Solubility: ≥ 2.5 mg/mL (5.91 mM); Clear solution

   此方案可获得 ≥ 2.5 mg/mL (5.91 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

   以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*